Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Weill Cornell Medicine has 1 pending office action in Biotechnology & Pharmaceuticals. This matter is assigned to 1 distinct examiner, SALMON, KATHERINE D, who is the busiest examiner with a workload matching the total pending count. The prosecution is limited to a single art unit. This concentration suggests that the company's current USPTO activity is focused under a sole examiner's review.
With only a single pending matter, the company's interaction with the office is highly streamlined. The busiest examiner is responsible for the entirety of the pending workload, ensuring that there are no conflicting examination styles to manage. This parity between actions and examiners allows for a focused prosecution strategy. Practitioners should note that the specific art unit involved will define the primary technical criteria for the portfolio.
Because the portfolio is small, the prosecution strategy is centralized. SALMON, KATHERINE D has a workload that represents the total volume of pending work for the company. This focus in Biotechnology & Pharmaceuticals allows for a direct approach to addressing any rejections. The practitioner can concentrate on the specific tendencies of the assigned examiner without needing to reconcile different behaviors across multiple groups.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18647657 | FLUORESCENT SENSORS AND METHODS OF MAKING AND USING | SALMON, KATHERINE D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18647657 | FLUORESCENT SENSORS AND METHODS OF MAKING AND USING | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647657 | FLUORESCENT SENSORS AND METHODS OF MAKING AND USING | SALMON, KATHERINE D | 1682 | §101§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWeill Cornell Medicine has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katherine D Salmon has the most, with 1 of Weill Cornell Medicine's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.